# Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis

> **NCT07122648** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Paean Biotechnology Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Polymyositis
- Dermatomyositis

## Interventions

- **BIOLOGICAL:** placebo
- **BIOLOGICAL:** PN-101
- **BIOLOGICAL:** PN-101

## Key facts

- **NCT ID:** NCT07122648
- **Lead sponsor:** Paean Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07122648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07122648, "Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07122648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*